RhumbLine Advisers
FULC icon

RhumbLine Advisers’s Fulcrum Therapeutics FULC Stock Holding History

RhumbLine Advisers’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$508K Buy
66,175
+10,462
+19% +$97K ﹤0.01% 2601
2025
Q4 		$630K Sell
55,713
-13,659
-20% -$139K ﹤0.01% 2528
2025
Q3 		$638K Sell
69,372
-13,878
-17% -$100K ﹤0.01% 2531
2025
Q2 		$573K Sell
83,250
-5,743
-6% -$30.7K ﹤0.01% 2599
2025
Q1 		$256K Buy
88,993
+386
+0.4% +$1.42K ﹤0.01% 2980
2024
Q4 		$416K Buy
88,607
+1,399
+2% +$5.16K ﹤0.01% 2782
2024
Q3 		$311K Sell
87,208
-4,224
-5% -$31.3K ﹤0.01% 3002
2024
Q2 		$567K Buy
91,432
+89,775
+5,418% +$680K ﹤0.01% 2582
2024
Q1 		$15.6K Hold
1,657
– – ﹤0.01% 3799
2023
Q4 		$11.2K Hold
1,657
– – ﹤0.01% 3849
2023
Q3 		$7.36K Sell
1,657
-3,134
-65% -$13.7K ﹤0.01% 3922
2023
Q2 		$15.8K Sell
4,791
-70,716
-94% -$208K ﹤0.01% 3853
2023
Q1 		$215K Buy
75,507
+15,777
+26% +$141K ﹤0.01% 2722
2022
Q4 		$435K Buy
59,730
+9,003
+18% +$58.7K ﹤0.01% 2532
2022
Q3 		$410K Buy
50,727
+3,200
+7% +$22.9K ﹤0.01% 2588
2022
Q2 		$233K Buy
47,527
+13,412
+39% +$131K ﹤0.01% 2872
2022
Q1 		$807K Buy
34,115
+2,408
+8% +$34.1K ﹤0.01% 2220
2021
Q4 		$561K Buy
31,707
+1,508
+5% +$29.9K ﹤0.01% 2463
2021
Q3 		$852K Buy
30,199
+7,724
+34% +$146K ﹤0.01% 2298
2021
Q2 		$236K Buy
22,475
+10,120
+82% +$102K ﹤0.01% 2876
2021
Q1 		$146K Buy
12,355
+490
+4% +$6.06K ﹤0.01% 2890
2020
Q4 		$139K Buy
11,865
+1,250
+12% +$14.1K ﹤0.01% 2915
2020
Q3 		$84K Sell
10,615
-2,110
-17% -$25.4K ﹤0.01% 2895
2020
Q2 		$233K Buy
+12,725
New +$200K ﹤0.01% 2697

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

RhumbLine Advisers's FULC Position: Q1 2026 in Review

RhumbLine Advisers increased its Fulcrum Therapeutics (FULC) stake by 19% in Q1 2026, buying an estimated $97K and bringing the position to 66,175 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

RhumbLine Advisers first reported a position in FULC in Q2 2020 and has held it in 24 quarters since. The position peaked at $852K in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • RhumbLine Advisers held 66,175 shares of Fulcrum Therapeutics worth $508K as of Q1 2026.
  • RhumbLine Advisers bought 10,462 Fulcrum Therapeutics shares in Q1 2026, an estimated $97K.
  • Fulcrum Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2601 holding.
  • RhumbLine Advisers first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • RhumbLine Advisers's Fulcrum Therapeutics position peaked at $852K in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.